Renoprotective effect of liraglutide on diabetic nephropathy by modulation of Krüppel-like transcription factor 5 expression in rats
Journal of Pharmacy and Pharmacology · 02.12.2024 · 76 (12) · 1563-1571
DOI: 10.1093/jpp/rgae127 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 14.10.2024. Verfasst von Anfal F Bin Dayel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Liraglutide, Diabetic Nephropathies, Kruppel-Like Transcription Factors, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Objectives
Diabetic nephropathy (DN) is a serious consequence of diabetes that can develop through the lysophosphatidic acid axis. The purpose of this study was to determine whether the antidiabetic drug liraglutide can slow the development of diabetic kidney damage by altering the lysophosphatidic acid axis via KLF5.
Methods
Wistar albino rats were divided into nondiabetic and diabetic rats (resulting from an intraperitoneal streptozotocin dose of 30 mg/kg and a high-fat diet). These rats were further divided into four groups: nondiabetic control, liraglutide-treated nondiabetic, diabetic control, and liraglutide-treated diabetic. The nondiabetic and diabetic control groups received normal saline for 42 days, while the liraglutide-treated nondiabetic and diabetic groups received normal saline for 21 days, followed by a subcutaneous dose of liraglutide (200 μg/kg/day) for 21 days. Subsequently, serum levels of DN biomarkers were evaluated, and kidney tissues were histologically examined. The protein expression of PCNA, autotaxin, and KLF5 was detected. Key findings Liraglutide treatment in diabetic rats decreased DN biomarkers, histological abnormalities in kidney tissues, and the protein expression of PCNA, autotaxin, and KLF5.
Conclusion
Liraglutide can slow the progression of DN by modulating KLF5-related lysophosphatidic acid axis. Thus, liraglutide may be an effective treatment for preventing or mitigating diabetes-related kidney damage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
- PharmD Program, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
ORCID-Profile: Anfal F Bin Dayel, Asma S Alonazi
Zitieren
APA
Bin Dayel, A. F., Alrasheed, N. M., Alonazi, A. S., Alamin, M. A., Al-Mutairi, N. M., & Alateeq, R. A. (2024). Renoprotective effect of liraglutide on diabetic nephropathy by modulation of Krüppel-like transcription factor 5 expression in rats. Journal of Pharmacy and Pharmacology, 76(12), 1563-1571. https://doi.org/10.1093/jpp/rgae127
Vancouver
Bin Dayel AF, Alrasheed NM, Alonazi AS, Alamin MA, Al-Mutairi NM, Alateeq RA. Renoprotective effect of liraglutide on diabetic nephropathy by modulation of Krüppel-like transcription factor 5 expression in rats. Journal of Pharmacy and Pharmacology. 2024;76(12):1563-1571. doi:10.1093/jpp/rgae127
BibTeX
@article{BinDayel2024,
author = {Bin Dayel, Anfal F and Alrasheed, Nouf M and Alonazi, Asma S and Alamin, Maha A and Al-Mutairi, Nawal M and Alateeq, Raghad A},
title = {Renoprotective effect of liraglutide on diabetic nephropathy by modulation of Krüppel-like transcription factor 5 expression in rats},
journal = {Journal of Pharmacy and Pharmacology},
year = {2024},
volume = {76},
number = {12},
pages = {1563--1571},
doi = {10.1093/jpp/rgae127}
}
EUVIMED